Arbutus Biopharma Cp (ABUS) Stock Price, Quote & News

Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the poten...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 469 0914

Website: www.arbutusbio.com

Address:

701 Veterans Circle, Warminster, United States

Grtgooglymoogly Nov. 14 at 9:26 PM

$ABUS Anybody find Goldman Sachs on Fintel for their quarter holdings of Abus?....they were adding the quarter before..

1 · Reply

JarvisFlow Nov. 14 at 8:57 PM

Chardan Capital has adjusted their stance on Arbutus Biopharma ( $ABUS ), setting the rating to Buy with a target price of 5.

1 · Reply

Shortsales Nov. 14 at 8:17 PM

$ROIV $ABUS

2 · Reply

HedgeAlerts Nov. 14 at 6:07 PM

Hedge Alert Live - Protect Your Portfolio Contract: $ABUS $4.00 Put · NOV 21, 2025 Exp Entry Price: $0.20 - $0.50 Exit Price Target: $0.27 Profit Margin: +37% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

SpaceCityKid Nov. 14 at 4:51 PM

$ABUS As per Morningstar, there are still 9.92M shares short (10/31/25). The clock is ticking

0 · Reply

Gugger Nov. 14 at 4:30 PM

$ABUS 😉

1 · Reply

LiquidThetaOptions Nov. 14 at 4:10 PM

💎 LiquidTheta® Live Actionable Trade Asset: $ABUS Contracts: $ABUS January 15, 2027 $5 Calls Scale in: $1.35- $1.65 Scale out: $5.25-$9.00 Profit Potential : 433% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Alfalcon Nov. 14 at 3:18 PM

$ABUS

0 · Reply

renoH4 Nov. 14 at 2:51 PM

$ABUS @CapitalismUSA it is only my opinion that Pfizer could buy the rights for the Hepatitis products and pay his patent bill - so together our profit could be 25 -33 $/share only from Pfizer and in the first quarter 2026 Moderna should lose the case and pay triple royalities plus interest : may be 15 - 20 $/share. Therefore i buy every dip if possible ( since years ) but now we see the light at the end of the tunnel. Count the days for the Pfizer deal and count the months for the Moderna drama.

1 · Reply

CapitalismUSA Nov. 14 at 1:18 PM

$ABUS I hope they decide to sell the HBV program. It will cost too much IMO to fund additional clinical trials, even in partnership. Thoughts?

3 · Reply

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 7, 2025, 8:00 AM EDT - 5 weeks ago

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Aug 6, 2025, 7:30 AM EDT - 3 months ago

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 25, 2025, 7:30 AM EDT - 5 months ago

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

May 14, 2025, 7:30 AM EDT - 6 months ago

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025, 2:01 AM EDT - 6 months ago

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Apr 23, 2025, 2:01 AM EDT - 7 months ago

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Mar 27, 2025, 7:56 AM EDT - 8 months ago

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Mar 27, 2025, 7:30 AM EDT - 8 months ago

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Mar 3, 2025, 9:15 AM EST - 9 months ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ROIV

Feb 25, 2025, 7:00 AM EST - 9 months ago

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Jan 30, 2025, 3:40 PM EST - 10 months ago

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.

BUR CDZI

Jan 13, 2025, 7:30 AM EST - 10 months ago

Arbutus Provides 2025 Corporate and Financial Update

Jan 7, 2025, 7:56 AM EST - 11 months ago

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Dec 3, 2024, 8:00 AM EST - 1 year ago

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Nov 26, 2024, 7:30 AM EST - 1 year ago

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Nov 15, 2024, 11:02 AM EST - 1 year ago

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Nov 14, 2024, 7:30 AM EST - 1 year ago

Arbutus to Present at Jefferies London Healthcare Conference

Nov 6, 2024, 2:52 PM EST - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 15, 2024, 8:16 AM EDT - 1 year ago

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Two Upcoming Investor Conferences

Aug 1, 2024, 2:00 PM EDT - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jul 5, 2024, 5:29 AM EDT - 1 year ago

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Jun 6, 2024, 11:15 AM EDT - 1 year ago

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Jun 5, 2024, 2:30 AM EDT - 1 year ago

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Jun 3, 2024, 9:50 AM EDT - 1 year ago

Arbutus Distributors Ltd. News Release

May 29, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Jefferies Global Healthcare Conference

May 22, 2024, 2:00 AM EDT - 1 year ago

Arbutus to Present Imdusiran Data at EASL Congress 2024

May 17, 2024, 9:00 AM EDT - 1 year ago

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

May 2, 2024, 1:15 PM EDT - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript

May 2, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 7:25 AM EDT - 1 year ago

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

Apr 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Apr 4, 2024, 8:30 AM EDT - 1 year ago

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Feb 29, 2024, 1:05 PM EST - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 7:30 AM EST - 1 year ago

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 15, 2024, 7:30 AM EST - 1 year ago

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Jan 8, 2024, 7:30 AM EST - 2 years ago

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Nov 9, 2023, 4:01 PM EST - 2 years ago

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Nov 7, 2023, 11:06 AM EST - 2 years ago

Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 7:30 AM EST - 2 years ago

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 7:15 AM EST - 2 years ago

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Oct 24, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Oct 18, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

Oct 11, 2023, 8:05 AM EDT - 2 years ago

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

Sep 11, 2023, 4:15 PM EDT - 2 years ago

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

Grtgooglymoogly Nov. 14 at 9:26 PM

$ABUS Anybody find Goldman Sachs on Fintel for their quarter holdings of Abus?....they were adding the quarter before..

1 · Reply

JarvisFlow Nov. 14 at 8:57 PM

Chardan Capital has adjusted their stance on Arbutus Biopharma ( $ABUS ), setting the rating to Buy with a target price of 5.

1 · Reply

Shortsales Nov. 14 at 8:17 PM

$ROIV $ABUS

2 · Reply

HedgeAlerts Nov. 14 at 6:07 PM

0 · Reply

SpaceCityKid Nov. 14 at 4:51 PM

$ABUS As per Morningstar, there are still 9.92M shares short (10/31/25). The clock is ticking

0 · Reply

Gugger Nov. 14 at 4:30 PM

$ABUS 😉

1 · Reply

LiquidThetaOptions Nov. 14 at 4:10 PM

0 · Reply

Alfalcon Nov. 14 at 3:18 PM

$ABUS

0 · Reply

renoH4 Nov. 14 at 2:51 PM

1 · Reply

CapitalismUSA Nov. 14 at 1:18 PM

$ABUS I hope they decide to sell the HBV program. It will cost too much IMO to fund additional clinical trials, even in partnership. Thoughts?

3 · Reply

JB6791 Nov. 14 at 1:09 PM

$ABUS Nice!!! 22 cent drop on 1200 volume 🤣🤣🤣

2 · Reply

HedgeAlerts Nov. 14 at 7:27 AM

Hedge Alert Live - Protect Your Portfolio Contract: $ABUS $4.00 Put · NOV 21, 2025 Exp Entry Price: $0.20 - $0.75 Exit Price Target: $0.27 Profit Margin: +36% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

EdDwg Nov. 14 at 3:08 AM

$ABUS

0 · Reply

CoinFlipTrader9 Nov. 13 at 9:37 PM

$ABUS saw the corporate update published for Nov25 https://investor.arbutusbio.com/static-files/34c4f6bf-1ad0-4673-aa57-0f6c3b9d268d

0 · Reply

hman62 Nov. 13 at 9:11 PM

$ABUS just another bad timing to release earnings. It really is amazing how many times ABUS releases ER or PR over the years and the market takes a big sh*t that same day. uncanny.

1 · Reply

Heavey Nov. 13 at 8:46 PM

$ABUS look at it this way, earlier this week we were hovering around $4.60, so today’s not too bad…

1 · Reply

Grtgooglymoogly Nov. 13 at 6:57 PM

$ABUS How long do rulings on Daubert motions typically take? Because I'm assuming the summary judgement rulings will come after the Daubert rulings.....

1 · Reply

LASTOCKS19 Nov. 13 at 5:46 PM

$ABUS Start of slow walk back? no news, low float, heavy dark-pool activity… Short interest ~7.9% of float, 11 days to cover, off-exchange ratio spiking. Could year-end rotation, tax-loss selling, or institutional rebalancing be suppressing price before Q1 catalysts? Can I get my low 4s is the question =)?

1 · Reply

Jan1010 Nov. 13 at 3:50 PM

$ABUS good progress but 1) why they did not ask the FDA for Fast track designation for Imdusiran 2) no disclosure of phase 2B or phase 3 of Imdusiran inspite of better results and achieving functional cure for most of the treatment subjects. 3) why AB-101 phase 2 study information was not disclosed. Behind the doors they are seriously cooking something….. Wait to hear reg the big BO or partnership info soon🔥💥☄️☄️🐂🐂🎁🎁

2 · Reply

renoH4 Nov. 13 at 3:28 PM

$ABUS ..what can we do against these criminal manipulations ? Everybody should send a letter or an e-mail to the government - write in social media or have a phone with Donald Trump. Explain the manipulation to the whole world. And talk about the unpaid patent bill about billions. Since years they have stolen our profit again and again for their short games!

1 · Reply

CapitalismUSA Nov. 13 at 3:17 PM

$ABUS Criminal manipulation….added to my A-BUS

1 · Reply

hman62 Nov. 13 at 2:59 PM

$ABUS well there is the predicted drop always after Earnings. got in at $4.50. but past history has in green by end of day. lets see. good report. just games as usual Shake and Bake

0 · Reply

Market Cap	592.57M
Revenue (ttm)	18.14M
Net Income (ttm)	-72.85M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	649,900
Avg Vol	936,122
Day's Range	N/A - N/A
Shares Out	188.72M
Stochastic %K	2%
Beta	1.98
Analysts	Strong Sell
Price Target	$4.50